BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 33855784)

  • 1. Eltrombopag in children with severe aplastic anemia.
    Lesmana H; Jacobs T; Boals M; Gray N; Lewis S; Ding J; Kang G; Hale M; Weiss M; Reiss U; Wang W; Wlodarski M
    Pediatr Blood Cancer; 2021 Aug; 68(8):e29066. PubMed ID: 33855784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A real-word experience of eltrombopag plus rabbit antithymocyte immunoglobulin-based IST in Chinese patients with severe aplastic anemia.
    Jin Y; Li R; Lin S; Jia J; Yang Y; Zhang D; He G; Li J
    Ann Hematol; 2022 Nov; 101(11):2413-2419. PubMed ID: 36028583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eltrombopag added to immunosuppression for children with treatment-naïve severe aplastic anaemia.
    Groarke EM; Patel BA; Gutierrez-Rodrigues F; Rios O; Lotter J; Baldoni D; St Pierre A; Shalhoub R; Wu CO; Townsley DM; Young NS
    Br J Haematol; 2021 Feb; 192(3):605-614. PubMed ID: 33410523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of immunosuppressive therapy with or without eltrombopag in pediatric patients with acquired aplastic anemia: A Chinese retrospective study.
    Fang M; Song H; Zhang J; Li S; Shen D; Tang Y
    Pediatr Hematol Oncol; 2021 Oct; 38(7):633-646. PubMed ID: 33724146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frontline Therapy Options for Adults With Newly Diagnosed Severe Aplastic Anemia: Intensive immunosuppressive Therapy Plus Eltrombopag or Matched Sibling Donor Hematopoietic Stem Cell Transplantation?
    Huang LF; Li L; Jia JS; Yang Y; Lin SY; Meng FK; Zhang DH; He GS
    Transplant Cell Ther; 2022 Sep; 28(9):586.e1-586.e7. PubMed ID: 35609866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of eltrombopag in the first-line therapy of severe aplastic anemia in children.
    Jie M; Fu L; Li S; He Y; Yao J; Cheng X; Zhang L; Zheng J; Zhang R; Wu R
    Pediatr Hematol Oncol; 2021 Oct; 38(7):647-657. PubMed ID: 33798022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy and safety of eltrombopag in aplastic anemia: A multi-center survey in China].
    Yang WR; Han B; Chang H; Wu BY; Meng FK; Ji DX; Li YM; Zheng ZJ; Fei Y; Shen JP; Hu P; Ding XQ; Zhang P; Wang YQ; Zhang FK
    Zhonghua Xue Ye Xue Za Zhi; 2020 Nov; 41(11):890-895. PubMed ID: 33333690
    [No Abstract]   [Full Text] [Related]  

  • 8. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.
    Townsley DM; Scheinberg P; Winkler T; Desmond R; Dumitriu B; Rios O; Weinstein B; Valdez J; Lotter J; Feng X; Desierto M; Leuva H; Bevans M; Wu C; Larochelle A; Calvo KR; Dunbar CE; Young NS
    N Engl J Med; 2017 Apr; 376(16):1540-1550. PubMed ID: 28423296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study.
    Patel BA; Groarke EM; Lotter J; Shalhoub R; Gutierrez-Rodrigues F; Rios O; Quinones Raffo D; Wu CO; Young NS
    Blood; 2022 Jan; 139(1):34-43. PubMed ID: 34525188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of eltrombopag in severe aplastic anemia.
    Scheinberg P
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):450-456. PubMed ID: 30504345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of immunosuppressive therapy combined with eltrombopag for severe aplastic anemia: a systematic review and meta-analysis.
    Zhang Y; Li J; Li X; Geng Q; Xie Y; Zhang G; Wei M; Ma Y
    Syst Rev; 2024 Apr; 13(1):101. PubMed ID: 38576005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of eltrombopag in severe aplastic anemia.
    Scheinberg P
    Blood Adv; 2018 Nov; 2(21):3054-3062. PubMed ID: 30425070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.
    Peffault de Latour R; Kulasekararaj A; Iacobelli S; Terwel SR; Cook R; Griffin M; Halkes CJM; Recher C; Barraco F; Forcade E; Vallejo JC; Drexler B; Mear JB; Smith AE; Angelucci E; Raymakers RAP; de Groot MR; Daguindau E; Nur E; Barcellini W; Russell NH; Terriou L; Iori AP; La Rocca U; Sureda A; Sánchez-Ortega I; Xicoy B; Jarque I; Cavenagh J; Sicre de Fontbrune F; Marotta S; Munir T; Tjon JML; Tavitian S; Praire A; Clement L; Rabian F; Marano L; Hill A; Palmisani E; Muus P; Cacace F; Frieri C; van Lint MT; Passweg JR; Marsh JCW; Socié G; Mufti GJ; Dufour C; Risitano AM;
    N Engl J Med; 2022 Jan; 386(1):11-23. PubMed ID: 34986284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eltrombopag, oral immunosuppressant and androgen combination therapy in twelve patients with refractory severe aplastic anemia.
    Gao Q; Zhang L; Zhao X; Zhu Y; Peng G; Li Y; Li Y; Li J; Song L; Ye L; Fan H; Zhou K; Yang W; Yang Y; Jing L; Zhang F
    Hematology; 2020 Dec; 25(1):341-347. PubMed ID: 32915111
    [No Abstract]   [Full Text] [Related]  

  • 15. Eltrombopag in aplastic anemia.
    Desmond R; Townsley DM; Dunbar C; Young NS
    Semin Hematol; 2015 Jan; 52(1):31-7. PubMed ID: 25578417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eltrombopag for the treatment of aplastic anemia: current perspectives.
    Lum SH; Grainger JD
    Drug Des Devel Ther; 2016; 10():2833-2843. PubMed ID: 27695288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upfront eltrombopag monotherapy induces stable hematologic remission in pediatric patients with nonsevere idiopathic aplastic anemia.
    Geng W; Kearney S; Nelson S
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27290. PubMed ID: 29932285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia.
    Assi R; Garcia-Manero G; Ravandi F; Borthakur G; Daver NG; Jabbour E; Burger J; Estrov Z; Dinardo CD; Alvarado Y; Hendrickson S; Ferrajoli A; Wierda W; Cortes J; Kantarjian H; Kadia TM
    Cancer; 2018 Nov; 124(21):4192-4201. PubMed ID: 30307606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world outcomes with immunosuppressive therapy for aplastic anemia in patients treated at the University of Michigan.
    Foucar CE; Foley DH; Aldous J; Burke PW; Pettit KR; Benitez LL; Perissinotti AJ; Marini BL; Boonstra P; Bixby DL
    Eur J Haematol; 2024 Mar; 112(3):424-432. PubMed ID: 37929654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series.
    Martynova A; Chiu V; Mert M; Hermel D; Weitz IC
    Ann Hematol; 2021 Apr; 100(4):933-939. PubMed ID: 33420879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.